# Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections

> **NCT02801383** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 100 (estimated)

## Conditions studied

- Cervical HPV-16 and / or HPV-18 Infection

## Interventions

- **DRUG:** Yallaferon®， the recombinant human interferon α-2b gel
- **OTHER:** gel without active ingredient

## Key facts

- **NCT ID:** NCT02801383
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-09
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2016-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02801383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02801383, "Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02801383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*